PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

- Duchatel, Ryan J., Jackson, Evangeline R., Kearney, Padraic S., Jamaluddin, M. Fairuz B., Douglas, Alicia M., Beitaki, Tyrone, McEwen, Holly P., Persson, Mika L., Hocke, Emily A., Jain, Vaibhav, Aksu, Michael, Manning, Elizabeth E., Parackal, Sarah G., Murray, Heather C., Verrills, Nicole M., Hua, Susan, Cairns, Murray J., Alvaro, Frank, Dayas, Christopher V., Dun, Matthew D., Hua, S, de Bock, CE, Colino-Sanguino, Y, Kiltschewskij, Dylan, Valdes-Mora, F, Tsoli, M, Ziegler, DS, Cairns, MJ, Raabe, EH, Vitanza, NA, Hulleman, E, Phoenix, TN, Koschmann, C, Alvaro, F, Findlay, Izac J., Dayas, CV, Tinkle, CL, Wheeler, H, Whittle, JR, Eisenstat, DD, Firestein, R, Mueller, S, Valvi, S, Hansford, JR, Ashley, DM, Mannan, Abdul, Gregory, SG, Kilburn, LB, Nazarian, J, Cain, JE, Dun, MD, Staudt, Dilana E., Thomas, Bryce C., Germon, Zacary P., Laternser, Sandra

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

- de la Nava, Daniel, Ausejo-Mauleon, Iker, Tallon-Cobos, Antonio Carlos, Hernandez-Osuna, Reyes, Marco-Sanz, Javier, Dhandapani, Laasya, Hervás-Corpión, Irati, Becher, Oren J., Nazarian, Javad, Mueller, Sabine, Phoenix, Timothy N., van der Lugt, Jasper, Laspidea, Virginia, Hernaez, Mikel, Guruceaga, E, Koschmann, C, Venneti, S, Allen, JE, Dun, Matthew D., Fueyo, J, Gomez-Manzano, C, Perez-Larraya, JG, Patiño-García, A, Gonzalez-Huarriz, Marisol, Labiano, S, Alonso, MM, Lacalle, Andrea, Casares, Noelia, Zalacain, Marta, Marrodan, Lucía, García-Moure, Marc, Ochoa, Maria C.

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

- Venneti, Sriram, Kawakibi, Abed Rahman, Ramage, Samuel, Chi, Andrew, Wen, Patrick Y., Arrillaga-Romany, Isabel, Batchelor, Tracy T., Butowski, Nicholas A., Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca A., de Groot, John, Ji, Sunjong, Mehta, M, Hall, MD, Daghistani, D, Cloughesy, TF, Ellingson, BM, Beccaria, K, Varlet, P, Kim, MM, Umemura, Y, Garton, H, Waszak, Sebastian M., Franson, A, Schwartz, J, Jain, R, Kachman, M, Baum, H, Burant, CF, Mottl, SL, Cartaxo, RT, John, V, Messinger, D, Sweha, StefanR, Qin, T, Peterson, E, Sajjakulnukit, P, Ravi, K, Waugh, A, Walling, D, Ding, Y, Xia, Z, Schwendeman, A, Hawes, D, Mota, Mateus, Yang, F, Judkins, AR, Wahl, D, Lyssiotis, CA, de la Nava, D, Alonso, MM, Eze, A, Spitzer, J, Schmidt, SV, Duchatel, Ryan J., Pun, Matthew, Dun, Matthew D., Cain, JE, Jiang, L, Stopka, SA, Baquer, G, Regan, MS, Filbin, MG, Agar, NYR, Zhao, L, Kumar-Sinha, C, Deogharkar, Akash, Mody, R, Chinnaiyan, A, Kurokawa, R, Pratt, D, Yadav, VN, Grill, J, Kline, C, Mueller, S, Resnick, A, Nazarian, J, Chung, Chan, Allen, JE, Odia, Y, Gardner, SL, Koschmann, C, Tarapore, Rohinton S.

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

- Jackson, Evangeline R., Duchatel, Ryan J., Le Grand, Marion, Kearney, Padraic S., Douglas, Alicia M., Findlay, Izac J., Germon, Zacary P., McEwen, Holly P., Beitaki, Tyrone S., Patabendige, Adjanie, Skerrett-Byrne, David A., Nixon, Brett, Staudt, Dilana E., Smith, Nathan D., Day, B, Manoharan, N, Nagabushan, S, Hansford, JR, Govender, D, McCowage, GB, Firestein, R, Howlett, M, Endersby, R, Persson, Mika L., Gottardo, NG, Alvaro, F, Waszak, SM, Larsen, MR, Colino-Sanguino, Y, Valdés-Mora, F, Rakotomalala, A, Meignan, S, Pasquier, E, Andre, N, Mannan, Abdul, Hulleman, E, Eisenstat, DD, Vitanza, NA, Nazarian, J, Koschmann, C, Mueller, S, Cain, JE, Dun, MD, Yadavilli, Sridevi, Parackal, Sarah, Game, Shaye, Chong, Wai Chin, Jayasekara, W. Samantha N.

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

- Messinger, Dana, Harris, Micah K., Qin, Tingting, Mullan, Brendan, Siada, Ruby, Ravindran, Ramya, Niculcea, Michael, Dowling, Abigail R., Bradin, Joshua, Ginn, Kevin F., Gener, Melissa A. H., Dorris, Kathleen, Cummings, Jessica R., Vitanza, Nicholas A., Schmidt, SV, Spitzer, J, Li, J, Filbin, MG, Cao, X, Castro, MG, Lowenstein, PR, Mody, R, Chinnaiyan, A, Thomas, Chase, Desprez, PY, McAllister, S, Dun, Matthew D., Hawkins, C, Waszak, SM, Venneti, S, Koschmann, C, Yadav, VN, Yang, Tao, Sweha, Stefan R., Woo, Rinette, Siddaway, Robert, Burkert, Martin, Stallard, Stefanie

Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas

- Przystal, Justyna M., Cosentino, Chiara Cianciolo, Biery, Matt C., Myers, Carrie, Olson, James M., Panditharatna, Eshini, Kritzer, Bettina, Mourabit, Sulayaman, Vitanza, Nicholas A., Filbin, Mariella G., de Iuliis, Geoffry N., Dun, Matthew D., Yadavilli, Sridevi, Koschmann, C, Cain, JE, Grotzer, MA, Waszak, SM, Mueller, S, Nazarian, J, Zhang, Jie, Laternser, Sandra, Bonner, Erin R., Prasad, Rachna, Dawood, Adam A., Lobeto, Nina, Chong, Wai Chin

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

- Liu, Ilon, Jiang, Li, Mire, Hafsa M., Madlener, Sibylle, Mayr, Lisa, Quezada, Michael A., Trissal, Maria, Panditharatna, Eshini, Ernst, Kati J., Vogelzang, Jayne, Gatesman, Taylor A., Halbert, Matthew E., Samuelsson, Erik R., Palova, Hana, Pokorna, P, Sterba, J, Slaby, O, Geyeregger, R, Diaz, A, Findlay, Izac J., Dun, Matthew D., Resnick, A, Suvà, ML, Marco Salas, Sergio, Jones, DTW, Agnihotri, S, Svedlund, J, Koschmann, C, Haberler, C, Czech, T, Slavc, I, Cotter, JA, Ligon, KL, Alexandrescu, S, Beck, Alexander, Yung, WKA, Arrillaga-Romany, I, Gojo, J, Monje, M, Nilsson, M, Filbin, MG, Hack, Olivia A., Jeong, Daeun, Shaw, McKenzie L., Englinger, Bernhard, LaBelle, Jenna